Menu
Meet the Program Commitee for 2025!
项目委员会
-
Aimad Torqui • Division Head Medicines Evaluation Board
Medicines Evaluation Board, Netherlands -
Antonella Cardone • Director
Cancer Patients Europe, Belgium -
Claudia Dollins, PhD, RAC • Vice President, Precision Medicines, Global Regulatory Affairs
GlaxoSmithKline, United States -
Estelle Michael • RWE Policy & External Engagement Lead
UCB, Belgium -
Gracy G Crane, PhD, MS • Policy Lead
Roche, United Kingdom -
Inka Heikkinen, MBA, MSc • Regulatory Policy Lead
Lundbeck, Denmark -
James Whitehead, MBA, MSc • Senior Director, Device & Digital Safety
AstraZeneca, United Kingdom -
Kate Porch • Associate Director, Global Labeling Centre of Excellence
Johnson & Johnson, United Kingdom -
Kostas Papadakis • Global Head of Oncology Market Access (International)
Bayer, Switzerland -
Lada Leyens, PhD, MSc • Senior Director, EUCAN regulatory head GI
Takeda, Switzerland -
Magda Chlebus, MA • Executive Director, Science Policy & Regulatory Affairs
EFPIA - European Federation of Pharmaceutical Industries and Associations, Belgium -
Mark Pellett, PhD, MSc, RPh • Senior Director and Group Manager
AstraZeneca, United Kingdom -
Momir Radulovic • Executive Director
Slovenian Medicines and Medical Devices Agency (JAZMP), Slovenia -
Monique Al, PhD • Special advisor CCMO
Central Committee on Research Involving Human Subjects (CCMO), Netherlands -
Nikos Dedes • Representative
European AIDS Treatment Group (EATG), Greece -
Rebecca Lumsden, PhD • Head of Regulatory Science & Policy EU/AMEE
Sanofi, United Kingdom -
Sabina Hoekstra-van den Bosch, PharmD, MSc, RPh • Global Director Regulatory Strategy
Tüv Süd, Netherlands -
Sabine Haubenreisser, PhD, MSc • Principal Scientific Administrator, Stakeholders and Communication Division
European Medicines Agency, Netherlands -
Sarah Pope Miksinski, PhD • Executive Director, CMC Regulatory Affairs
Gilead Sciences, United States -
Susanne Ausborn, PhD • Global Head International Regulatory Policy
Roche, Switzerland -
Tamara Di Carlantonio, MA • Regulatory Policy Lead
Roche, Switzerland -
Thomas Wejs Møller, MBA, MSc • Director Global Regulatory Affairs - Devices
Novo Nordisk, Denmark -
Tim Powell • Director, Submission Sciences, Global Safety and Regulatory Sciences
Biogen, United Kingdom -
Ursula Busse, PhD, MBA • Head of Regulatory Affairs
Tigen Pharma SA, Switzerland -
Willemijn van der Spuij, MSc • Executive Director, WorldWide Patient Safety International, Europe
Switzerland